A 484954

Target: A-484954 targets eukaryotic elongation factor 2 kinase, also known as eEF2K.

Mechanism of Action: A-484954 may be used as a target-binding warhead for degrader exploration against eEF2K. In a PROTAC format, an A-484954-derived ligand would provide selective recognition of the kinase, whereas an attached linker and E3 ligase ligand would recruit a cellular ubiquitin ligase. The intended bifunctional molecule must simultaneously engage eEF2K and the E3 complex to generate a ternary assembly. When this assembly positions lysine residues productively, eEF2K can be ubiquitinated and routed to the proteasome for degradation. This establishes a testable protein-depletion mechanism for research assays.

• PROTAC-Mediated Target Degradation: A 484954 ligand can be used as the binding module in PROTAC designs to recruit an E3 ubiquitin ligase and promote ubiquitination of the target protein. This enables systematic evaluation of degradation potency, including dose- and time-dependent loss of the target, and supports mechanistic studies of ubiquitin-dependent proteasomal turnover.

• E3 Ligase Recruitment Optimization: Incorporate the 484954 ligand into PROTAC scaffolds with different E3 ligase recruiters to tune ternary complex formation and degradation efficiency. Researchers can compare linker lengths, attachment sites, and stereochemistry to identify configurations that maximize target engagement while minimizing off-target degradation and non-specific ubiquitination.

• Structure-Guided PROTAC Design: Use the ligand’s binding properties to guide rational PROTAC optimization, including mapping contact residues and defining productive attachment points. This supports generation of PROTAC variants with improved cooperativity, enhanced ternary stability, and greater degradation selectivity, enabling structure-function relationships to be established for targeted protein elimination.

• Proteasome-Dependence Validation: Apply the 484954-based PROTAC in experiments that confirm degradation is driven by the ubiquitin-proteasome pathway. By combining PROTAC treatment with proteasome inhibition and assessing target recovery kinetics, researchers can distinguish true degradation from reversible inhibition and quantify the contribution of ubiquitination to net protein loss.

A-484954 is a selective eEF2K-directed small-molecule inhibitor that can serve as a target-binding starting point for degrader hypothesis testing. Its compact fused pyridopyrimidinedione scaffold and pendant amino/carboxamide functionality offer a chemically defined platform for linker feasibility assessment. This molecule is described in detail below.

Structure: The structure is described as 7-amino-1-cyclopropyl-3-ethyl-1,2,3,4-tetrahydro-2,4-dioxopyrido[2,3-d]pyrimidine-6-carboxamide. This fused heterocycle contains multiple carbonyl and amino hydrogen-bonding sites, with small alkyl/cyclopropyl substituents that preserve a compact kinase-inhibitor profile.

Reactivity: Because the scaffold contains an amino group and carboxamide, linker installation should be considered only after identifying a substituent position that tolerates extension without compromising eEF2K binding; direct modification of core hydrogen-bonding atoms may reduce activity. Initial PROTAC analogues could pair short-to-medium alkyl, PEG, or amide-linked linkers with CRBN or VHL ligands, while IAP or MDM2 recruiters may be reserved for broader E3-ligase profiling.